Abstract: Since January 2020 Elsevier has created a COVID-19 resource centre with
free information in English and Mandarin on the novel coronavirus COVID19. The COVID-19 resource centre is hosted on Elsevier Connect, the
company's public news and information website.
Elsevier hereby grants permission to make all its COVID-19-related
research that is available on the COVID-19 resource centre - including this
research content - immediately available in PubMed Central and other
publicly funded repositories, such as the WHO COVID database with rights
for unrestricted research re-use and analyses in any form or by any means
with acknowledgement of the original source. These permissions are
granted for free by Elsevier for as long as the COVID-19 resource centre
remains active.
research letter
www.kidney-international.org
Use of remdesivir in kidney transplant recipients
with SARS-CoV-2 Omicron infection
Judit Cacho1, David Nicolás2, Marta Bodro3, Elena Cuadrado-Payán1, Verónica Torres-Jaramillo1,
Ángela Gonzalez-Rojas1, Pedro Ventura-Aguiar1,2, Enrique Montagud-Marrahi1, Sabina Herrera3,
Veronica Rico2, Frederic Cofàn1, Frederic Oppenheimer1, Ignacio Revuelta1,4,5, Fritz Diekmann1,4,5,6 and
David Cucchiari1,4,6
1
Department of Nephrology and Kidney Transplantation, Hospital Clínic, Barcelona, Spain; 2Hospital-at-Home Unit, Department of
Internal Medicine, Hospital Clínic, Barcelona, Spain; 3Department of Infectious Diseases Service, Hospital Clínic-IDIBAPS, University of
Barcelona, Barcelona, Spain; 4Laboratori Experimental de Nefrologia i Trasplantament (LENIT), Institut d’Investigacions Biomèdiques
August Pi i Sunyer (IDIBAPS), Barcelona, Spain; and 5Red de Investigación Renal (REDINREN), Madrid, Spain
Kidney International (2022) 102, 917–921; https://doi.org/10.1016/
j.kint.2022.08.001
Copyright ª 2022, International Society of Nephrology. Published by
Elsevier Inc. All rights reserved.
Correspondence: David Cucchiari or Fritz Diekmann, Department of
Nephrology and Kidney Transplantation, Hospital Clínic, Carrer Villarroel 170
(Escala 12–Planta 5), 08036 Barcelona, Spain. E-mail: cucchiari@clinic.cat
(D. Cucchiari) or fdiekman@clinic.cat (F. Diekmann)
6
FD and DC are contributed equally to this work.
Received 20 April 2022; revised 27 July 2022; accepted 4 August 2022;
published online 11 August 2022
Kidney International (2022) 102, 917–921
I
nfection from the Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seems to be
less severe in general population in comparison with the
previous variants of concern.1 However, in kidney transplant
recipients (KTRs), Omicron continues to be a considerable
threat2 due to immunosuppression status and blunt response
to vaccination.3
Clinical trials with remdesivir have demonstrated
improved time to recovery in patients on oxygen with coronavirus disease 2019 (COVID-19).4 In Spain, it was approved
in September 2020 for the treatment of COVID-19 in patients
with pneumonia, respiratory failure, and less than 8 days
since symptoms’ onset. Then, in consideration of the Phase 3
Randomized, Double-Blind Placebo-Controlled Trial to
Evaluate the Efficacy and Safety of Remdesivir (GS-5734)
Treatment of COVID-19 in an Outpatient Setting (PINETREE), patients with mild symptomatology and comorbidities were also considered to receive treatment with remdesivir
because of its safety profile and the lower risk of hospitalization or death than placebo.5
Taking into consideration these..
{ 'indexed': {'date-parts': [[2024, 8, 3]], 'date-time': '2024-08-03T22:45:46Z', 'timestamp': 1722725146973},
'reference-count': 7,
'publisher': 'Elsevier BV',
'issue': '4',
'license': [ { 'start': { 'date-parts': [[2022, 10, 1]],
'date-time': '2022-10-01T00:00:00Z',
'timestamp': 1664582400000},
'content-version': 'tdm',
'delay-in-days': 0,
'URL': 'https://www.elsevier.com/tdm/userlicense/1.0/'}],
'content-domain': { 'domain': ['kidney-international.org', 'elsevier.com', 'sciencedirect.com'],
'crossmark-restriction': True},
'published-print': {'date-parts': [[2022, 10]]},
'DOI': '10.1016/j.kint.2022.08.001',
'type': 'journal-article',
'created': {'date-parts': [[2022, 8, 11]], 'date-time': '2022-08-11T15:14:30Z', 'timestamp': 1660230870000},
'page': '917-921',
'update-policy': 'http://dx.doi.org/10.1016/elsevier_cm_policy',
'source': 'Crossref',
'is-referenced-by-count': 12,
'title': 'Use of remdesivir in kidney transplant recipients with SARS-CoV-2 Omicron infection',
'prefix': '10.1016',
'volume': '102',
'author': [ {'given': 'Judit', 'family': 'Cacho', 'sequence': 'first', 'affiliation': []},
{'given': 'David', 'family': 'Nicolás', 'sequence': 'additional', 'affiliation': []},
{'given': 'Marta', 'family': 'Bodro', 'sequence': 'additional', 'affiliation': []},
{'given': 'Elena', 'family': 'Cuadrado-Payán', 'sequence': 'additional', 'affiliation': []},
{ 'given': 'Verónica',
'family': 'Torres-Jaramillo',
'sequence': 'additional',
'affiliation': []},
{'given': 'Ángela', 'family': 'Gonzalez-Rojas', 'sequence': 'additional', 'affiliation': []},
{'given': 'Pedro', 'family': 'Ventura-Aguiar', 'sequence': 'additional', 'affiliation': []},
{'given': 'Enrique', 'family': 'Montagud-Marrahi', 'sequence': 'additional', 'affiliation': []},
{'given': 'Sabina', 'family': 'Herrera', 'sequence': 'additional', 'affiliation': []},
{'given': 'Veronica', 'family': 'Rico', 'sequence': 'additional', 'affiliation': []},
{'given': 'Frederic', 'family': 'Cofàn', 'sequence': 'additional', 'affiliation': []},
{'given': 'Frederic', 'family': 'Oppenheimer', 'sequence': 'additional', 'affiliation': []},
{'given': 'Ignacio', 'family': 'Revuelta', 'sequence': 'additional', 'affiliation': []},
{'given': 'Fritz', 'family': 'Diekmann', 'sequence': 'additional', 'affiliation': []},
{'given': 'David', 'family': 'Cucchiari', 'sequence': 'additional', 'affiliation': []}],
'member': '78',
'reference': [ { 'key': '10.1016/j.kint.2022.08.001_bib1',
'doi-asserted-by': 'crossref',
'first-page': 'e304',
'DOI': '10.1097/TP.0000000000004126',
'article-title': 'Trends in COVID-19 outcomes in kidney transplant recipients during the '
'period of omicron variant predominance',
'volume': '106',
'author': 'Villanego',
'year': '2022',
'journal-title': 'Transplantation'},
{ 'key': '10.1016/j.kint.2022.08.001_bib2',
'doi-asserted-by': 'crossref',
'first-page': '1241',
'DOI': '10.1016/j.ekir.2022.03.020',
'article-title': 'Early administration of anti–SARS-CoV-2 monoclonal antibodies prevents '
'severe COVID-19 in kidney transplant patients',
'volume': '7',
'author': 'Gueguen',
'year': '2022',
'journal-title': 'Kidney Int Rep'},
{ 'key': '10.1016/j.kint.2022.08.001_bib3',
'doi-asserted-by': 'crossref',
'first-page': '2727',
'DOI': '10.1111/ajt.16701',
'article-title': 'Cellular and humoral response after mRNA-1273 SARS-CoV-2 vaccine in '
'kidney transplant recipients',
'volume': '21',
'author': 'Cucchiari',
'year': '2021',
'journal-title': 'Am J Transplant'},
{ 'key': '10.1016/j.kint.2022.08.001_bib4',
'doi-asserted-by': 'crossref',
'first-page': '1813',
'DOI': '10.1056/NEJMoa2007764',
'article-title': 'Remdesivir for the treatment of Covid-19—final report',
'volume': '383',
'author': 'Beigel',
'year': '2020',
'journal-title': 'N\xa0Engl J Med'},
{ 'key': '10.1016/j.kint.2022.08.001_bib5',
'doi-asserted-by': 'crossref',
'first-page': '305',
'DOI': '10.1056/NEJMoa2116846',
'article-title': 'Early remdesivir to prevent progression to severe Covid-19 in '
'outpatients',
'volume': '386',
'author': 'Gottlieb',
'year': '2022',
'journal-title': 'N\xa0Engl J Med'},
{ 'key': '10.1016/j.kint.2022.08.001_bib6',
'doi-asserted-by': 'crossref',
'first-page': '2305',
'DOI': '10.1016/j.ekir.2021.06.023',
'article-title': 'Use and safety of remdesivir in kidney transplant recipients with '
'COVID-19',
'volume': '6',
'author': 'Buxeda',
'year': '2021',
'journal-title': 'Kidney Int Rep'},
{ 'key': '10.1016/j.kint.2022.08.001_bib7',
'doi-asserted-by': 'crossref',
'first-page': 'e3990',
'DOI': '10.1093/cid/ciaa1851',
'article-title': 'Remdesivir use in the setting of severe renal impairment: a theoretical '
'concern or real risk?',
'volume': '73',
'author': 'Pettit',
'year': '2021',
'journal-title': 'Clin Infect Dis'}],
'container-title': 'Kidney International',
'original-title': [],
'language': 'en',
'link': [ { 'URL': 'https://api.elsevier.com/content/article/PII:S0085253822006135?httpAccept=text/xml',
'content-type': 'text/xml',
'content-version': 'vor',
'intended-application': 'text-mining'},
{ 'URL': 'https://api.elsevier.com/content/article/PII:S0085253822006135?httpAccept=text/plain',
'content-type': 'text/plain',
'content-version': 'vor',
'intended-application': 'text-mining'}],
'deposited': { 'date-parts': [[2024, 1, 11]],
'date-time': '2024-01-11T08:20:45Z',
'timestamp': 1704961245000},
'score': 1,
'resource': {'primary': {'URL': 'https://linkinghub.elsevier.com/retrieve/pii/S0085253822006135'}},
'subtitle': [],
'short-title': [],
'issued': {'date-parts': [[2022, 10]]},
'references-count': 7,
'journal-issue': {'issue': '4', 'published-print': {'date-parts': [[2022, 10]]}},
'alternative-id': ['S0085253822006135'],
'URL': 'http://dx.doi.org/10.1016/j.kint.2022.08.001',
'relation': {},
'ISSN': ['0085-2538'],
'subject': [],
'container-title-short': 'Kidney International',
'published': {'date-parts': [[2022, 10]]},
'assertion': [ {'value': 'Elsevier', 'name': 'publisher', 'label': 'This article is maintained by'},
{ 'value': 'Use of remdesivir in kidney transplant recipients with SARS-CoV-2 Omicron '
'infection',
'name': 'articletitle',
'label': 'Article Title'},
{'value': 'Kidney International', 'name': 'journaltitle', 'label': 'Journal Title'},
{ 'value': 'https://doi.org/10.1016/j.kint.2022.08.001',
'name': 'articlelink',
'label': 'CrossRef DOI link to publisher maintained version'},
{'value': 'article', 'name': 'content_type', 'label': 'Content Type'},
{ 'value': '© 2022 International Society of Nephrology. Published by Elsevier Inc. All '
'rights reserved.',
'name': 'copyright',
'label': 'Copyright'}]}
